Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Valproate-associated hyperammonemic encephalopathy Wadzinski J; Franks R; Roane D; Bayard MJ Am Board Fam Med 2007[Sep]; 20 (5): 499-502The use of valproic acid (VPA) (also known as Depakote, Depakene, and others) frequently results in elevated plasma ammonia. In some people, hyperammonemia may be clinically significant, resulting in hyperammonemic encephalopathy, which may be severe. Valproic acid-induced hyperammonemic encephalopathy may occur in people with normal liver function, despite normal doses and serum levels of VPA. We describe 2 cases of valproic acid-induced hyperammonemic encephalopathy in patients with supratherapeutic VPA levels, although the condition has been described in people with normal VPA levels. With the increasing indications and off-label uses of VPA, family physicians should be aware of this potential complication of VPA and check ammonia levels in patients taking VPA who present with alterations in mental status. Treatment with L-carnitine may be beneficial in reducing ammonia levels.|Antimanic Agents/*adverse effects[MESH]|Bipolar Disorder/drug therapy[MESH]|Cognition Disorders/chemically induced[MESH]|Coma/chemically induced[MESH]|Female[MESH]|Humans[MESH]|Hyperammonemia/*chemically induced/diagnosis/physiopathology/therapy[MESH]|Middle Aged[MESH]|Neurotoxicity Syndromes/diagnosis/*etiology/physiopathology/therapy[MESH]|Stress Disorders, Post-Traumatic/drug therapy[MESH]|Valproic Acid/*adverse effects[MESH] |
